```html

Medication‑Related Jawbone Osteonecrosis (MRONJ)

Overview

Medication‑related jawbone osteonecrosis (MRONJ) is a rare but serious condition in which the bone tissue of the jaw (maxilla or mandible) becomes exposed and fails to heal, eventually leading to necrosis (death) of bone. The condition occurs most commonly in patients taking anti‑resorptive or anti‑angiogenic medications such as bisphosphonates (e.g., alendronate, zoledronic acid) and denosumab, as well as certain cancer‑targeted therapies (bevacizumab, sunitinib).

• Who it affects: Primarily adults over 50 years, especially those with cancer (multiple myeloma, breast, prostate) or severe osteoporosis.
• Prevalence: Reported incidence varies widely:
  • Oral bisphosphonates: 0.001–0.01 % in osteoporosis patients.
  • IV bisphosphonates (zoledronic acid, pamidronate): 0.5–5 % in oncology patients.
  • Denosumab (Xgeva®): up to 1.8 % in cancer patients; 0.004 % in osteoporosis patients.
  (Mayo Clinic, CDC).

MRONJ is defined by the American Association of Oral and Maxillofacial Surgeons (AAOMS) as:

Exposed bone in the maxilla or mandible that persists for >8 weeks in a patient who has taken anti‑resorptive or anti‑angiogenic medication, with no history of radiation therapy to the head and neck.

Symptoms

Symptoms may appear slowly and can be mild at first, so vigilance is essential. Common signs include:

• Exposed bone: A visible area of dead bone in the gum, often painless at first.
• Pain or soreness: Dull, throbbing, or sharp pain in the jaw, which may worsen with chewing.
• Swelling: Localized swelling of the gums, lips, or face.
• Redness or inflammation: Irritated, inflamed gingival tissue surrounding the lesion.
• Foul odor or taste: Due to secondary infection or necrotic tissue.
• Loose teeth or loss of teeth: Teeth around the necrotic area may become mobile or fall out.
• Difficulty opening the mouth (trismus): Reduced range of motion caused by inflammation or muscular involvement.
• Numbness or paraesthesia: Altered sensation in the lower lip, chin, or tongue.
• Pathologic fracture: In severe cases, the necrotic bone can fracture spontaneously.
• Non‑healing extraction socket: An extraction site that fails to close within the expected timeframe (usually >8 weeks).

Causes and Risk Factors

Medications that trigger MRONJ

• Bisphosphonates – oral (alendronate, risedronate) and intravenous (zoledronic acid, pamidronate). They inhibit osteoclast‑mediated bone resorption.
• Denosumab – a monoclonal antibody that blocks RANK‑L, decreasing osteoclast activity (Xgeva®, Prolia®).
• Anti‑angiogenic agents – bevacizumab, sunitinib, sorafenib, which impair blood vessel formation and bone healing.
• Tyrosine‑kinase inhibitors – especially those used in renal cell carcinoma and other solid tumors.

Key risk factors

• Potent IV anti‑resorptives – higher risk than oral formulations.
• Duration of therapy – risk rises after 2 years of continuous treatment, especially >4 years.
• Dental extractions or invasive oral surgery – the most common precipitating event.
• Pre‑existing periodontal disease, caries, or ill‑fitting dentures.
• Concurrent corticosteroid use – systemic steroids impair wound healing.
• Smoking, diabetes, or immunosuppression – all reduce vascular supply.
• Older age & female gender – reflects higher osteoporosis treatment rates.

Diagnosis

MRONJ is a clinical diagnosis supported by imaging and laboratory studies. The evaluation typically includes:

Clinical examination

• Inspection for exposed bone or non‑healing mucosal defects.
• Palpation for tenderness, induration, and assessment of tooth mobility.
• Evaluation of mouth opening (measure interincisal distance).

Radiographic imaging

• Panoramic radiograph (OPG) – first‑line; may reveal radiolucent areas, cortical bone loss, or sequestra.
• Cone‑beam CT (CBCT) – provides three‑dimensional detail, useful for surgical planning.
• CT or MRI – indicated when there is suspicion of soft‑tissue involvement or pathologic fracture.

Laboratory tests

• Complete blood count and inflammatory markers (CRP, ESR) – to identify infection.
• Serum calcium, vitamin D, and renal function – especially before altering bisphosphonate therapy.

Staging (AAOMS 2022)

Stage	Clinical features
0	Non‑exposed bone disease – nonspecific symptoms (pain, radiographic changes) without exposed bone.
1	Exposed bone, no infection, minimal symptoms.
2	Exposed bone with infection, pain, and swelling.
3	Exposed bone with extensive infection, pathologic fracture, or extraoral fistula.

Treatment Options

Therapy is individualized based on stage, patient health, and medication history.

Conservative (non‑surgical) management – Stages 0‑2

• Oral antimicrobial rinses – 0.12 % chlorhexidine twice daily.
• Systemic antibiotics – amoxicillin‑clavulanate or clindamycin for infection (duration 2–6 weeks).
• Pain control – acetaminophen, NSAIDs (if no contraindication), or low‑dose opioids for severe pain.
• Topical agents – tetracycline paste or platelet‑rich fibrin to promote mucosal healing.
• Medication holiday – temporary cessation of bisphosphonates/denosumab (typically 2–3 months) after multidisciplinary discussion; evidence for benefit is limited but may aid healing in selected cases.

Surgical intervention – Stages 2‑3

• Sequestrectomy – removal of dead bone fragments.
• Debridement and primary closure – smoothing of bone edges and tension‑free mucosal flap to cover the defect.
• Resection/reconstruction – for extensive disease or pathologic fracture, may require microvascular free‑flap surgery.
• Adjunctive therapies – laser biostimulation, ozone therapy, or hyperbaric oxygen (HBOT) – data are mixed, but may be considered in refractory cases.

Lifestyle & supportive measures

• Good oral hygiene – soft‑bristled brush, fluoride toothpaste, interdental cleaners.
• Avoidance of traumatic dental procedures; if extractions are unavoidable, coordinate with the prescribing physician.
• Smoking cessation and glycemic control (for diabetics).
• Nutrition – a balanced diet with adequate protein, calcium, and vitamin D.

Living with Jawbone Osteonecrosis (Medication‑Related)

Daily oral care routine

1. Brush gently twice daily with a soft‑bristled toothbrush.
2. Use a non‑alcoholic antiseptic rinse (chlorhexidine) after meals.
3. Floss once daily with a floss threader or water flosser to avoid vigorous mechanical stress.
4. Inspect the mouth each night for any new lesions or changes.

Dietary tips

• Favor soft, nutrient‑dense foods (yogurt, smoothies, scrambled eggs) during flare‑ups.
• Avoid extremely hot or cold foods that may aggravate exposed bone.
• Limit acidic or highly seasoned foods that can irritate gingiva.

Follow‑up schedule

After the initial diagnosis:

• Stage 0‑1: dental review every 3 months.
• Stage 2‑3: visits every 4–6 weeks during active treatment, then every 6 months once stable.

Psychological & social support

Chronic oral pain and altered appearance can affect quality of life. Encourage patients to:

• Seek counseling or support groups (e.g., American Cancer Society survivorship programs).
• Discuss prosthetic options (partial dentures, implants after disease remission) with a prosthodontist.

Prevention

Because MRONJ is largely iatrogenic, prevention centers on communication between the prescribing physician, dentist, and patient.

• Dental assessment before starting anti‑resorptives – complete periodontal exam, treat caries, and extract hopeless teeth well before medication initiation.
• Drug holidays when feasible – especially before invasive dental work; discuss risks/benefits with the oncologist or endocrinologist.
• Maintain optimal oral hygiene – regular professional cleanings every 6 months.
• Avoid elective extractions or implants while on high‑dose IV bisphosphonates or denosumab unless absolutely necessary.
• Manage comorbidities – control diabetes, stop smoking, limit corticosteroid use where possible.

Complications

If MRONJ is not adequately treated, several serious outcomes may develop:

• Secondary infection – cellulitis, osteomyelitis, or deep neck space infection that can progress to sepsis.
• Pathologic fracture – weakened mandibular bone may fracture spontaneously, requiring surgical fixation.
• Fistula formation – abnormal communication between the oral cavity and skin (extraoral fistula) or sinus.
• Nutritional deficiencies – difficulty chewing leads to weight loss and protein‑energy malnutrition.
• Reduced quality of life – chronic pain, speech difficulties, and psychosocial distress.

When to Seek Emergency Care

---

© 2026 HealthGuide™ – All information provided is for educational purposes only and does not replace personal medical advice. Consult your healthcare provider for diagnosis and treatment tailored to your individual circumstances.

References:

• American Association of Oral and Maxillofacial Surgeons. “AAOMS Position Paper on MRONJ.” 2022.
• Mayo Clinic. “Medication‑related osteonecrosis of the jaw.” Link
• Cleveland Clinic. “Bisphosphonate‑Related Osteonecrosis of the Jaw.” 2023.
• National Institutes of Health – National Cancer Institute. “Bone‑Targeting Agents and Oral Health.” 2022.
• World Health Organization. “Pharmacovigilance of anti‑resorptive agents.” 2021.

```